Vistusertib not checked

AstraZeneca · AZD2014

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
6 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive oral tablets of vistusertib as stated in arm description.”In the company’s words, NCT03334617 on ClinicalTrials.gov
Tested for
Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer
Main trialPhase 2
“This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.”In the company’s words, NCT03334617 on ClinicalTrials.gov
Other names
AZD2014

Other drugs for Non-Small Cell Lung Cancer

All 560 drugs for Non-Small Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 13 Sep 2024 Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Phase 1Active, not recruiting 18 Mar 2020 Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Phase 1/2Terminated 20 Nov 2019 A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Phase 1Completed 4 Aug 2016 AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
Phase 1Completed 30 Mar 2018 Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
Phase 1Completed 12 Apr 2024 Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Vistusertib

Following is part of Solo: you see every change to Vistusertib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in